Capital Markets, SVB, Foot & Ankle Innovation
Startup capital is the fuel for innovation in foot and ankle surgery. There are several sources for capital with debt financing through banks representing one of them. Competition is good and the more banks willing to lend the more likely that new concepts, products, and creativity will appear in our operating rooms. But if there is trouble brewing in the capital markets, startup capital will become more difficult, and more expensive, to come by.
Silicon Valley Bank (SVB)
SVB was not a common name in the Orthopedic sector before last week. Now you'd have to be living under a rock to have missed its Twitter-fueled collapse.
Foot & Ankle and SVB
Nothing negative here for our industry. While Treace Medical had a relationship with SVB, by this report it has had no negative exposure to the collapse.
Recent Posts
See AllBioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million. Indu
Dr. Ned Amendola MD, FAAOS, FRCS(C) from Duke University was named second vice president of the American Academy of Orthopedic Surgeons (AAOS) and will ascend to president in 2025-2026. Fellowship tra
As speculated in February 2023 FIX, Enovis announced early this week that it has consummated a deal for Novastep with the MIS bunion system being the prize along with access to a robust OUS sales chan
